- District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
- Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
- Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
- Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
- Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
More ▼
Key statistics
On Friday, Liquidia Corp (LQDA:NAQ) closed at 13.77, -18.95% below its 52-week high of 16.99, set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.03 |
---|---|
High | 14.03 |
Low | 13.55 |
Bid | 13.52 |
Offer | 13.95 |
Previous close | 13.92 |
Average volume | 833.92k |
---|---|
Shares outstanding | 76.38m |
Free float | 66.73m |
P/E (TTM) | -- |
Market cap | 1.09bn USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼